dosage – Ayurved Healing

Bacopa Monnieri Dosage Guide: What Clinical Trials Actually Used

Dr. Meera Iyer — Tue, 17 Mar 2026 11:00:00 +0000

In a randomized, double-blind trial published in 2001, 46 healthy adults received either placebo or 300 mg daily of the proprietary Bacopa monnieri extract KeenMind for 12 weeks. The active treatment was given as two 150 mg tablets and was described as a 20:1 extract standardized to at least 55% combined bacosides A and B. Compared with placebo, the Bacopa group showed improvements in selected measures of visual information processing, verbal learning and memory consolidation, with the strongest effects recorded at the 12-week assessment.

That study illustrates the central problem in any Bacopa dosage guide: “300 mg” is meaningful only when the plant material, extraction ratio, standardization, schedule and duration are also known. A proprietary extract, a whole-plant powder and another extract are not automatically equivalent, even when their labels show the same milligram amount.

Why the Preparation Determines the Dose

The Ayurvedic Pharmacopoeia of India identifies Brahmi as the dried whole plant of Bacopa monnieri. Modern cognitive trials, by contrast, usually administered concentrated extracts. Extraction changes how much starting herb is represented in each tablet, while standardization describes selected constituents measured by a particular analytical method. Both details matter when comparing a supplement with a published trial.

KeenMind/CDRI 08 in the 2001 and 2008 Stough trials was a 20:1 ethanolic extract standardized to at least 55% combined bacosides A and B. The extract used by Calabrese and colleagues was prepared from dried aerial parts at a 50:1 ratio and standardized to a minimum of 50% bacosides A and B. Peth-Nui and colleagues used an ethanol extract containing 5% total saponins by HPLC. These percentages describe different preparations and should not be treated as interchangeable measures of potency.

Clinical Trial Doses at a Glance

The following table summarizes well-described human studies relevant to cognition, memory or attention. It separates chronic adult trials from acute and pediatric research because a single experimental dose and a months-long daily regimen answer different questions.

Chronic Studies in Adults

Most influential adult trials lasted about 12 weeks, but they did not all use the same extract, participant group or outcome battery. Improvements were generally selective rather than uniform across every cognitive test.

Study	Participants	Daily Dose and Preparation	Duration	Main Reported Finding
Stough et al. (2001)	46 healthy adults, 18-60 years	300 mg KeenMind; 20:1 extract; at least 55% combined bacosides A and B	12 weeks	Benefits on selected measures of visual information processing, verbal learning, memory consolidation and state anxiety; maximal effects at 12 weeks
Roodenrys et al. (2002)	76 adults, 40-65 years	300 mg for participants under 90 kg; 450 mg for those over 90 kg	3 months	Reduced forgetting of newly learned information; no significant effects on attention, working memory, short-term memory, retrieval of established knowledge or anxiety
Stough et al. (2008)	107 enrolled; 62 compliant completers	300 mg KeenMind; two 150 mg tablets; at least 55% combined bacosides A and B	90 days	Improvement in a working-memory factor, spatial working-memory accuracy and false-positive errors on rapid visual information processing
Calabrese et al. (2008)	54 adults aged 65 years or older; 48 completed	300 mg; 50:1 extract; minimum 50% bacosides A and B	12 weeks after a placebo run-in	Improved delayed word recall and one Stroop reaction-time measure; several other cognitive and mood measures did not differ from placebo
Morgan and Stevens (2010)	98 healthy adults over 55; 81 completed	300 mg BacoMind proprietary extract	12 weeks	Improved verbal learning, memory acquisition and delayed recall; several secondary tests improved over time without significant between-group differences
Peth-Nui et al. (2012)	60 healthy older adults	300 mg or 600 mg ethanol extract containing 5% total saponins	12 weeks	Changes in selected working-memory and event-related-potential measures, with reduced plasma acetylcholinesterase activity; no clear dose-dependent pattern

Acute and Pediatric Studies

These studies are useful for defining what was tested, but they do not establish a general self-care dose. Acute crossover work evaluates hours after one dose, while an uncontrolled pediatric study cannot separate treatment effects from expectancy, maturation or other changes over time.

Study	Design	Dose	Duration	Interpretation
Downey et al. (2013)	Randomized, double-blind, placebo-controlled crossover study in 24 healthy adults	Single 320 mg and 640 mg doses of CDRI 08	Acute testing	The 320 mg dose improved performance at several repetitions of a demanding cognitive battery; this was not a chronic daily-dose trial
Dave et al. (2014)	Open-label study in 31 children aged 6-12 years with ADHD	225 mg daily of BacoMind	6 months	Parent-rated symptom scores declined, but the absence of placebo and blinding substantially limits causal conclusions

What the Overall Pattern Supports

Across chronic adult research, 300 mg daily is the most frequently encountered extract dose, while some studies used 450 mg according to body weight or tested 600 mg in a distinct low-saponin extract. The recurring number does not make 300 mg a universal recommendation: the chemical profile and extraction method remain part of the dose.

Twelve weeks is the best-represented duration for memory research. The 2001 Stough trial found its strongest effects at week 12 rather than week 5. A systematic review of six randomized trials in adults without dementia or major cognitive impairment found that all included studies used 12-week treatment periods and doses from 300 to 450 mg daily. Across those trials, the most consistent signal was in free-recall memory tasks, with much less evidence for broad improvement across other cognitive domains.

Higher is not proven better. Roodenrys used 450 mg only for participants above a specified body weight, and Peth-Nui found no clear dose-response pattern between 300 mg and 600 mg of its own 5%-saponin extract. The acute 640 mg crossover dose cannot be used to justify 640 mg every day.

The findings do not establish treatment for a neurological or psychiatric disorder. The adult trials were small and usually enrolled cognitively healthy people. The pediatric ADHD study was open-label. Product-specific cognitive findings should therefore not be presented as proof that Bacopa treats ADHD, dementia, depression or anxiety.

Ayurvedic Pharmacopoeial Profile of Brahmi

The Ayurvedic Pharmacopoeia of India, Part I, Volume II, describes Brahmi as the dried whole plant of Bacopa monnieri. Its recorded rasa are madhura, tikta and kashaya; guna are laghu and sara; virya is shita; and vipaka is madhura. The listed karma include medhya and rasayana, along with kaphahara, vatahara, svarya, vishahara, ayushya, matiprada, prajasthapana and mohahara.

Official plant material	Dried whole plant of Bacopa monnieri
Rasa	Madhura, tikta, kashaya
Guna	Laghu, sara
Virya	Shita
Vipaka	Madhura
Pharmacopoeial powder dose	1-3 g

The same monograph lists Sarasvatarishta, Brahmi Ghrita, Brahmi Vati, Sarasvata Churna, Ratnagiri Rasa and Smritisagara Rasa. Its 1-3 g dose applies to whole-plant powder, not to a 20:1 or 50:1 extract, and it does not establish clinical equivalence with a proprietary tablet.

How to Read a Bacopa Label

A responsible comparison starts with the exact formulation rather than the largest milligram number. The following details determine whether a commercial product resembles any studied preparation.

Botanical identity and part: look for Bacopa monnieri and whether the whole plant or aerial parts were used.
Preparation: distinguish whole-plant powder from an extract and note the extraction ratio when supplied.
Standardization: record the stated bacoside or total-saponin percentage and the analytical specification; unlike percentages are not automatically comparable.
Daily amount: calculate the total daily dose rather than relying on the amount per capsule.
Trial match: a label that names KeenMind/CDRI 08, BacoMind or another proprietary extract should be compared only with trials that used that same preparation.

For Adults Considering a Standardized Extract

The most defensible summary is that several small adult trials used 300 mg daily of a specified extract for roughly 12 weeks. This is a description of the research, not an individualized prescription. Escalating to 450 or 600 mg because those numbers appear in another trial ignores body-weight rules, different standardizations and different study designs.

For Whole-Plant Powder

The API dose of 1-3 g refers to the official dried whole-plant powder. It should remain clearly separated from extract dosing. A practitioner may also choose an Ayurvedic formulation, vehicle and schedule according to the individual; a milligram-for-milligram substitution between powder, ghrita, arishta and concentrated extract is not valid.

For Children, Pregnancy and Complex Medical Care

Parents should not derive a pediatric dose from one uncontrolled study. Human safety information during pregnancy and lactation is insufficient for routine self-use. Children, pregnant or breastfeeding individuals, and people using prescription medicines should take Bacopa only after consultation with a qualified healthcare professional.

Adverse Effects and Interaction Precautions

Gastrointestinal effects are the most consistent adverse events in human reports. Morgan and Stevens recorded increased stool frequency, abdominal cramps and nausea; Calabrese and colleagues reported stomach upset; and the 2001 Stough trial recorded more nausea, dry mouth and fatigue in the Bacopa group. These trials were relatively small and short, so they do not establish long-term safety for every population or product.

Bacopa has cholinergic activity, while laboratory evidence suggests possible effects on drug-metabolizing enzymes and thyroid physiology. These findings warrant caution rather than proving that an interaction will occur. A pharmacist or physician should review use with cholinergic or anticholinergic medicines, thyroid treatment, or drugs with narrow safety margins.

Common Questions

These practical questions are best answered by preserving the distinction between traditional use, product labeling and the exact preparation evaluated in a clinical study.

Does 300 mg Always Mean the Same Thing?

No. In the cited trials, 300 mg referred variously to a 20:1 extract standardized to at least 55% combined bacosides, a 50:1 extract standardized to at least 50% bacosides, BacoMind, or an ethanol extract containing 5% total saponins. The milligram amount cannot be interpreted apart from the preparation.

How Soon Should Effects Be Judged?

For chronic memory outcomes, the most relevant comparison period is approximately 12 weeks because that is the duration used in the principal adult trials and systematic review. This does not guarantee benefit by 12 weeks, and it does not justify continuing indefinitely when adverse effects occur or when a clinician advises stopping.

References

Nothing in this article diagnoses or treats a medical condition. Use it as educational information and consult a qualified Ayurvedic practitioner or physician before starting herbs, supplements, detoxes, or therapeutic protocols, especially if pregnant, managing a condition, or taking medication.

Ashwagandha: The Most Complete Research Summary for Evidence-Based Practitioners

Dr. Meera Iyer — Mon, 09 Mar 2026 14:13:02 +0000

Ashwagandha (Withania somnifera (L.) Dunal) is promoted for stress, anxiety, sleep, cognition, hormones, thyroid function, and exercise performance. The evidence is uneven: most trials are small, short, and tied to a specific preparation, so findings from one extract or powder cannot automatically be transferred to another product.

The Ayurvedic Pharmacopoeia of India identifies Aśvagandhā as the dried mature root. It lists tikta and kaṣāya rasa, laghu guna, uṣṇa vīrya, madhura vipāka, and the actions rasāyana, vātakaphāpaha, balya, and vājīkaraṇa. Its powder dose is 3–6 g. This is not equivalent to the milligram dose of a concentrated extract, and classical properties should not be converted directly into claims for modern diagnosed diseases.

Moderate Evidence: Stress and Cortisol Reduction

Stress is the best-supported modern use, but “strong evidence” overstates certainty. A 2022 meta-analysis in Phytotherapy Research included 12 randomized-trial papers with 1,002 participants. Ashwagandha reduced stress (standardized mean difference −1.75; 95% CI −2.29 to −1.22) and anxiety (−1.55; 95% CI −2.37 to −0.74), but heterogeneity was high and certainty was rated low.

A 2021 review covered seven trials involving 491 adults treated for six to eight weeks. Studies used root extracts, root-and-leaf extracts, an unspecified extract, or root granules; extract doses ranged from 240 to 1,250 mg/day, while the granules equaled 6 g/day of root powder. Most reported improved perceived stress, and several reported lower cortisol, but the preparation differences prevent a universal dose recommendation.

In the Salve trial, 60 stressed adults received aqueous root extract at 125 mg twice daily, 300 mg twice daily, or placebo for eight weeks. Both active regimens improved stress measures and reduced cortisol. Confidence level: Moderate because samples were small, follow-up was short, and products and methods varied.

Limited-Moderate Evidence: Anxiety Reduction

Anxiety scores often improve in stress trials, but many participants had self-reported stress or mild symptoms rather than a rigorously diagnosed anxiety disorder. NCCIH states that some preparations may help stress and insomnia while evidence for anxiety remains unclear.

An international psychiatric taskforce provisionally discussed 300–600 mg/day of standardized root extract for generalized anxiety disorder while emphasizing that stronger evidence is needed. Ashwagandha should not replace psychotherapy, psychiatric assessment, or prescribed treatment. Confidence level: Limited to moderate.

Moderate Evidence: Sleep Quality

A 2021 meta-analysis included five randomized trials with 400 participants and found a small but significant overall sleep benefit (standardized mean difference −0.59; 95% CI −0.75 to −0.42). Effects were more prominent in adults with insomnia, at doses of at least 600 mg/day, and when treatment lasted at least eight weeks.

Four trials used KSM-66 root extract and one used Shoden root-and-leaf extract. Outcomes included sleep quantity, quality, latency, efficiency, and alertness on rising. Certain extracts may improve sleep, but they are not proven substitutes for evaluating chronic insomnia, sleep apnea, depression, medication effects, or thyroid disease. Confidence level: Moderate.

Limited-Moderate Evidence: Muscle Strength and Recovery

The 2015 Wankhede trial enrolled 57 healthy men aged 18–50 with little resistance-training experience. Participants received 300 mg of root extract twice daily or placebo during eight weeks of training. Mean bench-press strength rose by 46.0 kg with ashwagandha and 26.4 kg with placebo; leg-extension strength and selected muscle-size measures also improved more in the active group.

The trial additionally reported differences in testosterone, body-fat percentage, and serum creatine kinase. A 2026 meta-analysis pooled four strength studies involving 223 participants and found a favorable effect, but certainty for muscle strength was low and heterogeneity was moderate; pooled body weight and body-fat effects were not significant.

Confidence level: Limited to moderate; the findings do not justify broad claims for all athletes or preparations.

Limited Evidence: Testosterone and Male Fertility

In a 2019 crossover trial, overweight men aged 40–70 with mild fatigue received standardized Shoden extract for eight weeks. Compared with placebo, DHEA-S increased by 18% more and testosterone by 14.7% more.

The study found no significant between-group differences in fatigue, vigor, sexual well-being, psychological well-being, cortisol, or estradiol. A 2026 meta-analysis of seven testosterone studies involving 488 participants found a small pooled increase, but populations and preparations differed. NCCIH describes testosterone and sperm-quality evidence as limited.

Ashwagandha is not an established treatment for hypogonadism, erectile dysfunction, or infertility, and results from stressed, overweight, training, or subfertile populations should not be generalized to every healthy man. Confidence level: Limited and population-specific.

Preliminary Evidence and Caution: Thyroid Function

A double-blind trial in 50 adults with subclinical hypothyroidism compared 300 mg of root extract twice daily with placebo for eight weeks. TSH decreased and T3 and T4 increased in the active group. One small trial does not establish treatment for overt hypothyroidism, Hashimoto disease, hyperthyroidism, thyroid nodules, or patients stabilized on thyroid medicine.

NIH sources also describe thyroid-hormone changes and case reports of thyrotoxicosis that improved after ashwagandha was stopped. People with thyroid disease, abnormal tests, or thyroid medication should not use it without clinician supervision. Confidence level: Preliminary for benefit, with a meaningful safety signal.

Limited-Moderate Evidence: Cognition and Memory

A 2017 pilot trial randomized 50 adults with mild cognitive impairment to 300 mg of root extract twice daily or placebo for eight weeks. The active group improved on tests of immediate and general memory, executive function, sustained attention, and information-processing speed. This does not establish prevention or treatment of dementia or another neurological disease.

A 2026 meta-analysis included 20 studies with 1,249 participants across cognitive and physical outcomes. Pooled results favored ashwagandha for memory and attention or processing speed; certainty was moderate for these outcomes and low for executive function. Global cognition came from one study and was rated very low certainty. Confidence level: Limited to moderate for selected test outcomes.

Insufficient Evidence: Blood Sugar and Inflammation

A 2020 diabetes review found only five clinical studies alongside much more laboratory and animal research and concluded that human evidence was not robust enough for therapeutic use. Small studies have also measured inflammatory or oxidative-stress biomarkers, but biomarker changes do not prove treatment of inflammatory disease. NCCIH considers evidence insufficient for diabetes and most other promoted conditions.

Root Powder and Proprietary Extracts Are Not Interchangeable

“Ashwagandha” is not one uniform intervention. The pharmacopoeial drug is dried mature root; KSM-66 is a root extract; and Sensoril and Shoden are root-and-leaf extracts used at different doses and standardizations. Evidence belongs first to the exact preparation and regimen studied.

Preparation	Verified distinction	Main limitation
API root powder	Dried mature root; dose 3–6 g	Not directly convertible to extract milligrams
KSM-66	Root extract used in multiple trials	Results apply to comparable regimens
Sensoril	Root-and-leaf extract used in stress studies	Not identical to the official root drug
Shoden	Concentrated root-and-leaf extract	Lower mass does not prove superiority
Unspecified extract	Plant part or standardization may be unclear	Difficult to match reliably to research

A stated withanolide percentage is not a universal potency scale. Plant part, extraction, marker definition, dose, accompanying ingredients, duration, product quality, and patient population all affect whether research applies to a commercial supplement.

Safety Summary

Ashwagandha may be reasonably tolerated for short-term use, generally up to about three months, but long-term safety is unknown. Reported effects include drowsiness, stomach upset, diarrhea, and vomiting.

Rare clinically apparent liver injury has been reported. LiverTox describes typical onset two to twelve weeks after starting ashwagandha, usually with cholestatic or mixed injury, jaundice, and itching. Most cases improve after stopping, but liver failure, transplantation, and deaths have occurred, particularly with pre-existing liver disease or cirrhosis. Avoid use in cirrhosis or advanced chronic liver disease and avoid rechallenge after suspected injury.

Important cautions and possible interactions include:

Pregnancy and breastfeeding: NCCIH advises avoidance.
Thyroid disorders or thyroid medicine: Hormone changes may interfere with treatment.
Sedatives and anticonvulsants: Additive nervous-system effects are possible.
Diabetes and blood-pressure medicines: Additive glucose- or pressure-lowering effects are possible.
Immunosuppressants or autoimmune disorders: Potential immune effects require caution.
Surgery: NCCIH does not recommend use when surgery is approaching.
Hormone-sensitive prostate cancer: Avoid use because testosterone may increase.

Stop use and seek medical assessment for jaundice, dark urine, severe itching, persistent vomiting, unusual fatigue, upper-abdominal discomfort, palpitations, tremor, or marked heat intolerance.

Dosage by Indication: Evidence Reference

No universal therapeutic dose is established. These are selected study regimens and the pharmacopoeial powder dose, not interchangeable prescriptions.

Outcome studied	Example regimen	Limitation
Perceived stress	125 or 300 mg aqueous root extract twice daily for 8 weeks	One product-specific trial
Stress/anxiety studies	Various extracts, 240–1,250 mg/day for 6–8 weeks	Preparations and scales varied
Sleep	Product-specific extracts; stronger subgroup signal at ≥600 mg/day and ≥8 weeks	Not a universal dose
Resistance training	300 mg root extract twice daily for 8 weeks	Key trial involved inexperienced men
Cognition	300 mg root extract twice daily for 8 weeks	Small pilot; other trials used other products
Subclinical hypothyroidism	300 mg root extract twice daily for 8 weeks	Single trial plus thyroid risk
Traditional root powder	API: 3–6 g	Not an extract conversion

The Bottom Line for Practitioners

The most defensible conclusion is that certain ashwagandha preparations may reduce perceived stress and modestly improve sleep during short-term use. Evidence for diagnosed anxiety disorders is less secure. Muscle strength, testosterone, cognition, male fertility, and thyroid effects remain limited, product-specific, or population-specific; evidence for treating diabetes and inflammatory disease is insufficient.

Responsible practice requires identifying the plant part and preparation, matching claims and doses to the tested product, and not assuming that short trials establish indefinite safety. Screen for pregnancy, breastfeeding, liver or thyroid disease, autoimmune disorders, surgery, hormone-sensitive prostate cancer, and interacting medicines. Consult a qualified Ayurvedic practitioner and an appropriate healthcare provider before medical use or use with prescription treatment.

This article is educational and does not diagnose, treat, or replace individualized care. Persistent anxiety, insomnia, fatigue, fertility concerns, cognitive symptoms, or abnormal thyroid, liver, glucose, or hormone results require professional assessment.

References

Ashwagandha Dosage Update: New Low-Dose Studies and Safety Data

Rohan Kapoor — Tue, 17 Feb 2026 07:30:00 +0000

Did you know that many modern Ashwagandha supplements are sold in the 300–600 mg/day extract range, while traditional Ayurvedic use is usually discussed in gram-level root-powder doses? A newer low-dose extract, Ashwa.30, has also brought attention to a much smaller 30 mg/day category. The important point is that these are not interchangeable.

Ashwagandha (Withania somnifera) is one of Ayurveda’s well-known rasayana herbs, traditionally used for vitality, debility, nervous restlessness, sleep support, memory support, and aggravated Vata. Modern supplement labels, however, often use standardized extracts rather than plain root powder, so dosage has to be understood by preparation type.

Here is a practical guide to Ashwagandha dosage, preparation style, safety, and daily use, with the traditional Ayurvedic position kept separate from standardized extract dosing.

The Low-Dose Category: 30 Milligrams

A 2025 PubMed-indexed paper describes Ashwa.30 as a bioactive-optimized, dual-standardized Withania somnifera extract designed for low-dose use around 30 mg/day. This is a specific proprietary extract, not a measure that can be transferred to generic Ashwagandha churna, capsules, or root powder.

The practical point is simple: 30 mg/day only makes sense when the product is that specific type of concentrated, standardized extract. A pinch of household Ashwagandha powder is not the same thing, and a 30 mg generic capsule should not be treated as equivalent to clinically used 300–600 mg root extracts.

Ashwagandha Dosage Tiers: What the Main Categories Mean

Ashwagandha dosage is easiest to understand in three tiers: low-dose optimized extracts, standard-dose standardized extracts, and traditional whole-root powder. The right tier depends on the preparation, the person’s constitution, the health goal, and professional guidance.

Tier 1: Low-Dose Optimized Extracts, Around 30–120 mg/day

This tier applies to specialized extracts designed for very low-dose use. It should not be used as a general rule for ordinary root powder or non-standardized capsules. When considering a low-dose product, the label should clearly state the extract name, plant part, standardization, and daily serving.

Tier 2: Standardized Extracts, Commonly 300–600 mg/day

This is the range most often seen in contemporary Ashwagandha trials for stress, sleep, cognition, and recovery. Many root-extract products are taken as 300 mg once or twice daily, often with food. A 2024 trial used 600 mg/day of Ashwagandha root extract in adults with self-reported cognitive and energy concerns, and a 2025 trial used 600 mg/day in female footballers for perceived recovery and sleep-quality outcomes.

Tier 3: Traditional Whole-Root Powder, Commonly About 3–6 g/day

This is the traditional gram-level approach used with dried Ashwagandha root powder, often taken with milk, ghee, or another suitable anupana. Official and regulatory monographs commonly place dried root use in the gram range, with 2–6 g/day or 3–6 g/day appearing in recognized Ayurvedic references and related monographs. Whole-root powder has an earthy, bitter-astringent taste; the Sanskrit name is commonly explained from ashwa meaning horse and gandha meaning smell, referring to the odour of the root.

How to Make Ashwagandha Ksheerapaka-Style Medicated Milk

In Ayurveda, Ashwagandha is often paired with nourishing carriers such as warm milk or ghee, especially when the intention is Vata support, strength, rest, and rejuvenation. A simple home preparation can be made gently and should be used in a dose appropriate for the individual.

Ashwagandha Milk Preparation

1 cup whole milk, or another suitable milk advised by a practitioner

1/2 teaspoon Ashwagandha root powder, approximately 2–3 g

1/4 teaspoon Shatavari powder, optional

A pinch of cardamom or nutmeg, optional

1/2 teaspoon ghee, optional

Jaggery to taste, or honey added only after the drink is warm rather than hot

Simmer the milk gently with Ashwagandha for about 5–10 minutes, stirring often. Add ghee near the end if using it. Let the drink cool to a comfortable warm temperature before adding honey. Take it in the evening only if it suits your constitution, digestion, and medical situation.

Shatavari in this recipe is optional, not mandatory. Ashwagandha and Shatavari have different Ayurvedic profiles, and the combination should be chosen according to constitution, digestion, heat tolerance, and the reason for use. People who feel heaviness, acidity, excess heat, loose stools, or daytime drowsiness should reduce the dose or stop and consult a qualified practitioner.

Ashwagandha Safety: Liver, Thyroid, Drowsiness, and Duration

Ashwagandha is generally well tolerated in short-term use for many adults, but long-term safety is not well established. Reported mild side effects include digestive upset, loose stools, nausea, and drowsiness. Caution is especially important for people with liver disease, thyroid conditions, autoimmune disease, hormone-sensitive prostate cancer, pregnancy, breastfeeding, or prescription medication use.

NIH LiverTox classifies Ashwagandha with a likelihood score of B for clinically apparent liver injury, meaning it is considered a likely cause in reported cases. The typical reported onset has been 2–12 weeks after starting Ashwagandha, often with jaundice and itching, and the pattern is commonly cholestatic or mixed. People with cirrhosis or advanced chronic liver disease should avoid Ashwagandha unless a qualified physician specifically advises otherwise.

A 2025 safety analysis comparing plant parts found a more favourable safety profile for Ashwagandha root than for non-root parts. This supports the traditional preference for root-based preparations and makes plant-part labeling important. Products that clearly identify “root” or “root extract” are preferable to unclear “whole plant” labels when safety is a priority.

A responsible safety checklist is: choose a clearly labeled root preparation; avoid combining multiple sedating supplements; do not exceed the label dose; avoid indefinite daily use without professional guidance; stop promptly if jaundice, dark urine, itching, severe fatigue, persistent nausea, or right-upper-abdominal pain appears; and seek medical care if liver-related symptoms occur.

Herb-Drug Interactions: What to Watch For

Ashwagandha has biological activity and can interact with medicines. Anyone taking prescription drugs should review Ashwagandha use with a qualified healthcare provider, especially when using standardized extracts.

Medication or Condition	Concern	Practical Guidance
Thyroid medication or thyroid disease	Ashwagandha may affect thyroid hormone levels in some people.	Use only with clinician awareness and thyroid monitoring.
Antidiabetes medication	Ashwagandha may affect glucose control.	Monitor glucose and avoid unsupervised combination use.
Antihypertensive medication	Ashwagandha may add to blood-pressure-lowering effects.	Watch for dizziness or lightheadedness and consult a clinician.
Immunosuppressants	Ashwagandha may not suit people needing immune suppression.	Avoid unless approved by the treating physician.
Sedatives, sleep medicines, alcohol	Drowsiness may be additive.	Avoid risky combinations and do not drive if sedated.
Pregnancy or breastfeeding	Safety is not established for self-use.	Avoid self-prescribing; consult a qualified healthcare provider.

Frequently Asked Questions

The most common Ashwagandha questions are not just about “how much,” but about which preparation, when to take it, and when to avoid it.

KSM-66 or Sensoril: Which Is Better?

KSM-66 is a root extract commonly used in the 300–600 mg/day range. Sensoril and Shoden are root-and-leaf extracts in some trials. For people prioritizing traditional root use and plant-part clarity, a root-only extract has an advantage. A root-and-leaf extract may still appear in modern products, but it should not be described as root-only.

Can Ashwagandha Be Taken With Brahmi?

Ashwagandha and Brahmi (Bacopa monnieri) are often considered together for stress, restlessness, and cognition, but they are not the same herb and should not be combined casually at high doses. Brahmi is traditionally known as a medhya rasayana for memory and intellect, while Ashwagandha is more strongly associated with strength, Vata support, vitality, and restoration.

Is Ashwagandha Safe During Pregnancy?

Ashwagandha should not be self-prescribed during pregnancy or breastfeeding. Regulatory and professional sources advise consultation before use in these situations, and several authorities recommend avoiding it in pregnancy because safety is not established for unsupervised supplement use.

What Is the Best Way to Take Ashwagandha Daily?

For a standardized root extract, many adults use 300 mg once or twice daily with food, according to the product label and professional guidance. For traditional root powder, the dose is gram-level and is often taken with warm milk or ghee. For evening use, start low because drowsiness can occur. For continuous use beyond a few months, or in anyone with liver, thyroid, autoimmune, hormonal, or medication concerns, professional supervision is important.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Ashwagandha may interact with prescription medications and may not be suitable for pregnancy, breastfeeding, liver disease, thyroid disorders, autoimmune conditions, or hormone-sensitive conditions. Consult a qualified Ayurvedic practitioner or healthcare provider before starting Ashwagandha or changing any supplement regimen.